- Management of Chronic Hepatitis B in Treatment-Naive Patients
-
Cheong JY
- KMID: 1767538
- Korean J Gastroenterol.
- 2008 Jun;51(6):338-345.
Chronic hepatitis B (CHB) is a serious health problem in Korea. The natural history of chronic HBV infection has been divided into 4 phases: immune tolerance, immune clearance, inactive HBsAg... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of Antiviral Resistance in Chronic Hepatitis B
-
Lim YS
- KMID: 2412184
- Gut Liver.
- 2017 Mar;11(2):189-195.
- doi: 10.5009/gnl15562
The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression. Hepatitis B surface antigen (HBsAg) seroclearance or seroconversion is regarded as an optimal endpoint... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of Antiviral-Resistant Chronic Hepatitis B Virus Infection
-
Yim HJ
- KMID: 1767539
- Korean J Gastroenterol.
- 2008 Jun;51(6):346-359.
Substantial progress has been made in the treatment of chronic hepatitis B during the past decade. Nucleos(t)ide analogues are now widely used due to their convenience, less side effects, and... -
- CITED
-
- Close
- SHARE
-
- Close
- Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B
-
Park MS, Kim BK, Kim KS, Kim JK, Kim SU, Park JY, Kim DY, Baartarkhuu O, Han KH, Chon CY, Ahn SH
- KMID: 1493572
- Clin Mol Hepatol.
- 2013 Mar;19(1):29-35.
- doi: 10.3350/cmh.2013.19.1.29
BACKGROUND/AIMS: The incidence of multidrug-resistant (MDR) chronic hepatitis B (CHB) during sequential lamivudine (LAM) and adefovir dipivoxil (ADV) treatment is increasing. We investigated the antiviral efficacies of various rescue regimens... -
- CITED
-
- Close
- SHARE
-
- Close
- Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
-
Song BC, Cho YK, Jwa H, Choi EK, Kim HU, Song HJ, Na SY, Boo SJ, Jeong SU
- KMID: 2070253
- Clin Mol Hepatol.
- 2014 Dec;20(4):355-360.
- doi: 10.3350/cmh.2014.20.4.355
BACKGROUND/AIMS: Spontaneous HBeAg seroconversion occurs frequently in the immune reactive phase in HBeAg-positive chronic hepatitis B (CHB). Therefore, observation for 3-6 months before commencing antiviral therapy is recommended in patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Expression of Hepatocyte Hepatitis B Core Antigen and Hepatitis B Surface Antigen as a Marker in the Management of Chronic Hepatitis B Patients
-
Yim SY, Kim TH, Jun SS, Kim ES, Keum B, Seo YS, Yim HJ, Jeen YT, Chun HJ, Lee HS, Um SH, Kim CD, Won NH, Ryu HS
- KMID: 2412216
- Gut Liver.
- 2017 May;11(3):417-425.
- doi: 10.5009/gnl16148
BACKGROUND/AIMS: We aimed to clarify the association of hepatitis B surface antigen (HBsAg)/hepatitis B core antigen (HBcAg) with the disease status and treatment response in patients with chronic hepatitis B... -
- CITED
-
- Close
- SHARE
-
- Close
- Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer
-
Hong J, Kyung SY, Lee SP, Park JW, Jung SH, Lee JI, Park SH, Sym SJ, Park J, Cho EK, Shin DB, Lee JH
- KMID: 1776611
- Korean J Intern Med.
- 2010 Sep;25(3):294-300.
- doi: 10.3904/kjim.2010.25.3.294
BACKGROUND/AIMS: The efficacy and safety of pemetrexed, gefitinib, and erlotinib administration in previously treated patients with non-small cell lung cancer (NSCLC) were compared. METHODS: The study patients met the following... -
- CITED
-
- Close
- SHARE
-
- Close
